Laws and Labels: A Regulatory View of Biosimilars

Friday, October 30, 2015
Presented by: 
Erika Lietzan

Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.

You may also like:

Blog Post

Adverse drug reactions from antibiotic exposure occur in one out of every five patients, according to two large studies of patients in the community and hospitalized patients, respectively. The community study measured emerge...

View Blog Post
Blog Post

The American Society of Automation in Pharmacy’s (ASAP) Midyear Conference brought more than 100 key technology executives together for three days of learning in Palm Beach, Florida. Thro...

View Blog Post
Blog Post

Medication errors are on the rise, particularly those that occur in the home, according to a recent study published in Clinical Toxicology. By analyzing data collected...

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up